Extrait

WO 39613 MORPHEUS : A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (Morpheus-muC)

Liens

• e-cancer.fr
• Fiche de l'U.S. National Library of Medicine (NLM), sur ClinicalTrials.gov